Rubius Therapeutics, Inc.

Sivan Elloul

Jordi Mata-Fink

Tiffany F Chen

Tom Wickham

Noubar Boghos Afeyan

Avak Kahvejian

Robert J Deans

John Round

Torben Straight Nissen

Nathan Dowden

Thomas Joseph Wickham

Lenka Hoffman

Xuqing Zhang

Carolyn Sayre

Billy Law

Kristian Eric Teichert

Shamael Rabia Dastagir

The present disclosure relates to erythroid cells that have been engineered to include, e.g., at the surface of the cell, one or more exogenous stimulatory polypeptides, wherein the exogenous stimulatory polypeptides presented are sufficient to stimulate an immune killer cell. The engineered enucleated cells of the present disclosure are useful in methods of activating NK cells and/or CD8+T-cells in a subject in need thereof, such as subjects having cancer or an infectious disease, and in particular cancers or infectious diseases characterized by downregulation of MHC Class I presentation.

Therapeutic cell systems and methods for treating cancer and infectious diseases

Described herein are novel preparations of functionalized erythroid cells and related compositions, reagents, and methods for use in human pharmaceutical and veterinary applications.

Functionalized erythroid cells

The invention includes compositions and methods related to multimodal therapies, e.g., for treating a cancer. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cancer.

Compositions and methods related to multimodal therapeutic cancer indications

Compositions and methods related to engineered erythroid cells comprising IL-15

Methods related to engineered erythoid cells comprising 4-1BBL

Compositions and methods related to engineered erythoid cells comprising 4-1BBL

Growing community of inventors

Newton, MA, United States of America

Sivan Elloul